<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092508</url>
  </required_header>
  <id_info>
    <org_study_id>197-02-220</org_study_id>
    <nct_id>NCT00092508</nct_id>
  </id_info>
  <brief_title>CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission</brief_title>
  <official_title>Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 mg QD of OPC-6335 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Ulcerative Colitis Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <brief_summary>
    <textblock>
      This dose comparison study, taking place at over 200 sites worldwide, will compare the&#xD;
      dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and&#xD;
      efficacy of Asacol ® in the maintenance of remission in subjects with ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective(s):&#xD;
&#xD;
      This study will compare the safety and efficacy of 25 mg per day (QD) and 50 mg QD of&#xD;
      OPC-6535 to 800 mg twice a day (BID) of Asacol® in the maintenance of remission in subjects&#xD;
      with ulcerative colitis.&#xD;
&#xD;
      Subject Population:&#xD;
&#xD;
        -  Subjects with ulcerative colitis currently in remission defined as rectal bleeding (RB)&#xD;
           and flexible sigmoidoscopy (FS) scores of 0, on or off a stable dose of sulfasalazine or&#xD;
           5-ASA products for at least 6 weeks.&#xD;
&#xD;
        -  Subjects must have had the diagnosis of ulcerative colitis established by prior&#xD;
           colonoscopy or undergo colonoscopy in lieu of flexible sigmoidoscopy during the&#xD;
           Screening Period.&#xD;
&#xD;
        -  Subjects must have had treatment for a flare of ulcerative colitis, with symptomatic&#xD;
           onset of remission occurring no more than 52 weeks from the Screening Period.&#xD;
&#xD;
        -  Subjects may not have used corticosteroids, topical agents (corticosteroid or 5-ASA&#xD;
           enemas, suppositories, foams), azathioprine, 6-mercaptopurine, or methotrexate within 6&#xD;
           weeks of the Screening Period. Upon entry, sulfasalazine and 5-ASA containing products&#xD;
           will be discontinued.&#xD;
&#xD;
      Safety: Vital signs, ECGs, laboratory studies (including hematology, clinical chemistry, and&#xD;
      urinalysis), and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">1725</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-6535</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 18 to 80 years of age, inclusive.&#xD;
&#xD;
          -  Subjects with a prior diagnosis of ulcerative colitis, established by colonoscopy.&#xD;
&#xD;
          -  Subjects currently in remission.&#xD;
&#xD;
          -  Subjects who have undergone treatment for a flare of ulcerative colitis, with&#xD;
             symptomatic onset of remission occurring no more than 52 weeks from the Screening&#xD;
             Period.&#xD;
&#xD;
          -  If subjects are taking sulfasalazine or 5-ASA products prior to entry, the dose must&#xD;
             be stable for at least 6 weeks prior to the Screening Period. NOTE: During the study,&#xD;
             use of these drugs will be discontinued.&#xD;
&#xD;
          -  Subjects having undergone colonoscopy with pan-colonic surveillance biopsies negative&#xD;
             for dysplasia within 1 year of the Screening Visit if at increased risk of colorectal&#xD;
             cancer (≥ 8 year history of ulcerative colitis).&#xD;
&#xD;
          -  Female or male subjects who are surgically sterilized or who are prepared to and agree&#xD;
             to practice a double-barrier form of birth control from the Screening Period through&#xD;
             30 days (females) and 90 days (males), respectively, from the last dose of study&#xD;
             medication. Females who are more than 12 months post-menopausal are also eligible to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have active disease.&#xD;
&#xD;
          -  Subjects who have any other clinically significant disease(s) or&#xD;
             condition/procedure(s).&#xD;
&#xD;
          -  Subjects who have had major gastrointestinal surgery including, but not limited to, a&#xD;
             colostomy, an ileostomy or previous colonic surgery other than appendectomy.&#xD;
&#xD;
          -  Subjects who have used corticosteroids or topical agents (corticosteroid or 5-ASA&#xD;
             enemas, suppositories, foams) within 6 weeks of the Screening Period.&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating.&#xD;
&#xD;
          -  Other exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Gastroenterology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark Lamet</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology Associates</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disorders Associates</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group</name>
      <address>
        <city>Chevy Cha</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates</name>
      <address>
        <city>Braintree</city>
        <state>Massachusetts</state>
        <zip>02184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists, PA</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive and Liver Diseases</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Gastroenterology Associates, PA</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroenterology Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethany Medical Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanover Medical Specialists, PA</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI &amp; Liver Consultants</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Clinic of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <last_update_submitted>June 19, 2007</last_update_submitted>
  <last_update_submitted_qc>June 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2007</last_update_posted>
  <keyword>Ulcerative Colitis Remission</keyword>
  <keyword>ulcerative</keyword>
  <keyword>colitis</keyword>
  <keyword>remission</keyword>
  <keyword>relapse</keyword>
  <keyword>Asacol®</keyword>
  <keyword>maintain</keyword>
  <keyword>maintenance</keyword>
  <keyword>flare</keyword>
  <keyword>rectal</keyword>
  <keyword>bleeding</keyword>
  <keyword>bowel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

